PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
NEW YORK and MELBOURNE, Australia, April 06, 2017 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that it has received A$3.7 million from the Australian Government for Research & Development (R&D) activities conducted during the 2016 financial year. The funds were provided to Mesoblast under the Government's R&D Tax Incentive Program, which is designed to support industry innovation.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast's actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
For further information, please contact: CORPORATE COMMUNICATIONS Julie Meldrum T: +61 3 9639 6036 E: [email protected] INVESTOR RELATIONS Schond Greenway T: +1 212 880 2060 E: [email protected]
